基石药业(02616.HK)获授抗体偶联药物LCB71韩国以外之开发及商业权
基石药业(02616.HK)公布,公司与LegoChem Biosciences订立授权协议,据此LegoChem授予独家许可以允许公司於韩国境外地区开发并商业化LCB71,一种以受体酪氨酸激(酉每)样孤儿受体1(ROR1)为靶点的临床前阶段抗体偶联药物。
LegoChem有权就开发、监管及商业里程碑收取总额为1,000万美元的预付款及总额为3.54亿美元的或然付款。此外,LegoChem有权收取基於LCB71净销售额的分层特许权使用费。於签立授权协议後,公司将负责承担於韩国境外地区LCB71所有正在进行的以及未来试验有关的开发和监管事务相关活动的所有费用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.